Senator Urges Consensus on Tobacco Law

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 2
Volume 7
Issue 2

WASHINGTON-Amid political bickering on Capitol Hill over the proposed tobacco settlement and the gloomy prediction of Senate Majority Leader Trent Lott (R-Miss) that legislation needed to implement the pact stands only a 30% chance of passage, a powerful Senate chairman gently warned public health groups that discord within their own ranks isn’t helping the situation.

WASHINGTON—Amid political bickering on Capitol Hill over the proposed tobacco settlement and the gloomy prediction of Senate Majority Leader Trent Lott (R-Miss) that legislation needed to implement the pact stands only a 30% chance of passage, a powerful Senate chairman gently warned public health groups that discord within their own ranks isn’t helping the situation.

In a letter to 34 organizations, including the American Medical Association and the American Cancer Society, Sen. John McCain (R-Ariz) urged the groups “to develop a consensus, where possible, concerning the key components of comprehensive tobacco legislation.”

Sen. McCain chairs the Committee on Commerce, Science, and Transportation, which will hold a series of hearings on the settlement proposal and play a major role in writing any tobacco law.

“The importance of a public health coalition reaching a common position on the details of the settlement cannot be overstated,” he said. “Legislative progress would be seriously impeded if the public health community is not fully engaged and substantially in accord.”

Sen. McCain said that Congress must address “extremely complex issues related to the tobacco settlement and national tobacco policy” and that consensus will be critical to drafting legislation that will win the support of the public, Congress, and the Clinton Administration.

“Clearly, the public health community must play a vital role in the process if we are to craft an appropriate legislative approach,” he said.

Recent Videos
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
4 experts in this video
4 experts in this video